Table 3 Factors associated with 30-day mortality by univariate and multivariate analysis
30-day survivors (n = 19) | 30-day non-survivor (n = 21) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
OR (95%CI) | p | OR (95% CI) | p | |||
Female, n (%) | 8 (44) | 6 (29) | ||||
Age, years | 57 (46–61) | 55 (41–62) | 1 (1.0–1.0) | 0.882 | ||
SOFA score | 8 (6–11) | 14 (10–16) | 1.3 (1.1–1.6) | 0.001 | 1.5 (1.1–2.1) | 0.01 |
Geographic origin, French Guyana, n (%) | 5 (33) | 8 (40) | 1.3 (0.3–5.8) | 0.707 | ||
Time between | ||||||
Symptom onset and ICU admission, days | 15 (10–28.5) | 28 (20–34) | 1.0 (1.0–1.1) | 0.078 | ||
Symptom onset and treatment, days | 16 (11–32) | 29 (21–40) | 1.0 (1.0–1.1) | 0.078 | 1.1 (1.0–1.1) | 0.02 |
ICU admission and treatment, days | 1 (0–2) | 2 (0–4) | 1.1 (0.9 –1.3) | 0.139 | ||
Underlying immunodeficiency | ||||||
HIV-infected, n (%) | 9 (47) | 14 (67) | – | 0.151 | ||
Other immunodeficiency, n (%) | 8 (42) | 3 (14) | 0.26 (0.0–1.2) | |||
No identified immunodeficiency, n (%) | 2 (11) | 4 (19) | 1.2 (0.2–11.7) | |||
Clinical features | ||||||
Temperature, °C | 39 (38–40) | 39 (38–40) | 0.9 (0.6–1.5) | 0.891 | ||
Neurological symptoms, n (%) | 5 (26) | 11 (52) | 3.0 (0.8–12.4) | 0.175 | ||
Respiratory symptoms, n (%) | 19 (100) | 19 (90) | 0.488 | |||
Gastrointestinal symptoms, n (%) | 11 (58) | 12 (57) | 1.0 (0.3–3.5) | 1.0 | ||
Biological data | ||||||
Lactate, mmol/L | 2 (2 –3) | 3 (2 –5) | 1.6 (1.0–2.4) | 0.035 | ||
Ferritinemia, UI/L | 10000 (3000–35000) | 40000 (40000–47500) | 1.0 (1.0–1.0) | 0.012 | ||
Platelets, G/L | 92 (54–205) | 26 (12–96) | 1.0 (1.0–1.0) | 0.096 | ||
Creatinine, µmol /L | 102 (70–344) | 206 (110–476) | 1.0 (1.0–1.0) | 0.110 | ||
Triglycerides, mmol/L | 2.5 (2.3–4.0) | 3.1 (2.9–3.3) | 1.1 (0.5–2.8) | 0.569 | ||
LDH, UI/L | 500 (400–935) | 989 (468–1224) | 1.0 (1.0–1.0) | 0.317 | ||
CRP, mg/L | 150 (87–222) | 146 (95–255) | 1.0 (1.0–1.0) | 0.910 | ||
Severe organ involvement | ||||||
Acute respiratory failure, n (%) | 16 (84) | 18 (86) | 1.1 (0.2–7.4) | 1.0 | ||
Shock, n (%) | 10 (53) | 21 (100) | < 0.001 | |||
Coma, n (%) | 3 (16) | 9 (43) | 3.8 (0.9–21.1) | 0.128 | ||
Hemophagocytic lymphohistiocytosis, n (%) | 4 (21) | 15 (71) | 8.6 (2.1–42.6) | 0.004 | 6.4 (1.1–47.5) | 0.05 |
Disseminated histoplasmosis, n (%) | 15 (79) | 17 (81) | 1.1 (0.2–5.3) | 0.878 | ||
Advanced life support therapy | ||||||
Renal replacement therapy, n (%) | 6 (32) | 16 (76) | 6.5 (1.7–29.2) | 0.006 | ||
Mechanical ventilation, n (%) | 10 (53) | 21 (100) | < 0.001 | |||